Information
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT) complied with federal securities laws. On
Original sourceAI Summary
Corcept is under investigation for potential securities law violations. FDA issued a Complete Response Letter for relacorilant on December 31, 2025. Corcept's stock price dropped following the FDA's response. Shareholders who lost money are encouraged to contact legal representatives. Holzer & Holzer, a top securities litigation firm, is leading the investigation.
Sentiment Rationale
The FDA's Complete Response Letter negatively affects investor confidence and future revenue potential, similar to past instances where FDA rejections significantly impacted stock pricing.
Trading Thesis
The immediate fallout from FDA reactions and potential investigations will likely influence stock prices quickly, similar to prior FDA responses affecting biotech firms.
Market-Moving
- Corcept is under investigation for potential securities law violations.
- FDA issued a Complete Response Letter for relacorilant on December 31, 2025.
- Corcept's stock price dropped following the FDA's response.
Key Facts
- Corcept is under investigation for potential securities law violations.
- FDA issued a Complete Response Letter for relacorilant on December 31, 2025.
- Corcept's stock price dropped following the FDA's response.
- Shareholders who lost money are encouraged to contact legal representatives.
- Holzer & Holzer, a top securities litigation firm, is leading the investigation.
Companies Mentioned
- VRTX (VRTX)
- SRPT (SRPT)
- CRSP (CRSP)
Corporate Developments
The article highlights significant compliance and regulatory issues that could influence investor behavior and market perception of CORT.
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT) complied with federal securities laws. On December 31, 2025, Corcept disclosed that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. Following this news, the price of the Company's stock dropped.
If you purchased Corcept stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/corcept-therapeutics/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025 dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
